Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.
Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Mendoza T, et al. Among authors: dumbrava e. J Immunother Cancer. 2020 Oct;8(2):e000931. doi: 10.1136/jitc-2020-000931. J Immunother Cancer. 2020. PMID: 33097611 Free PMC article.
Hypopigmented Skin Lesions After Immunotherapy.
Dumbrava EI, Ivan D, Subbiah V. Dumbrava EI, et al. JAMA Oncol. 2018 Aug 1;4(8):1118-1119. doi: 10.1001/jamaoncol.2018.0186. JAMA Oncol. 2018. PMID: 29801033 Free PMC article. No abstract available.
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. Owusu-Brackett N, et al. Among authors: dumbrava ei. Oncotarget. 2019 Aug 20;10(49):5011-5019. doi: 10.18632/oncotarget.27082. eCollection 2019 Aug 20. Oncotarget. 2019. PMID: 31489111 Free PMC article.
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.
Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Dumbrava EI, et al. JCO Precis Oncol. 2019;3:PO.18.00143. doi: 10.1200/PO.18.00143. Epub 2019 Apr 11. JCO Precis Oncol. 2019. PMID: 31517177 Free PMC article.
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Subbiah V, et al. Exp Hematol Oncol. 2020 Apr 20;9:7. doi: 10.1186/s40164-020-00159-1. eCollection 2020. Exp Hematol Oncol. 2020. PMID: 32337094 Free PMC article.
Engineered T-cell Receptor T Cells for Cancer Immunotherapy.
Greenbaum U, Dumbrava EI, Biter AB, Haymaker CL, Hong DS. Greenbaum U, et al. Cancer Immunol Res. 2021 Nov;9(11):1252-1261. doi: 10.1158/2326-6066.CIR-21-0269. Cancer Immunol Res. 2021. PMID: 34728535 Review.
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Mendoza TR, et al. Among authors: dumbrava e. Sci Rep. 2022 Aug 23;12(1):14367. doi: 10.1038/s41598-022-16588-3. Sci Rep. 2022. PMID: 35999229 Free PMC article. Clinical Trial.
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Nelson BE, et al. Among authors: dumbrava e. Cancer. 2023 Jul 15;129(14):2201-2213. doi: 10.1002/cncr.34773. Epub 2023 Apr 4. Cancer. 2023. PMID: 37016732 Free article. Clinical Trial.
62 results